BioSpace News Archive

Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, reported its financial and operational results for the third quarter of its fiscal year 2020, ending December 31, 2019.

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ended December 31, 2019. “The Company closed 2019 on a strong, positive trajectory, and we look at the past year as one of

iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today that it has enrolled the first patient in its Phase 1/2 study with EOS884448 (EOS-448), the company’s investigational ADCC-enabled antagonist anti-TIGIT antibody drug candidate.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), today presented at the American Academy of Pain Medicine’s 36th Annual Meeting.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will participate at the following upcoming investor conferences in March 2020 : The Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 . A corporate presentation is scheduled for 8:40 a.m. Eastern Time

Celprogen Inc., a global leader in the Stem Cell Research and Therapeutics industry for stem cell research since 2002, today announced that they have been awarded the ISO 9001-2015 Certification; the internationally recognized standards to ensures that our products and services meet the needs of our global clients through an effective quality management system.

Stealth BioTherapeutics (NASDAQ: MITO), today announced that Reenie McCarthy , CEO, will present at the 40 th Annual Cowen Health Care Conference in Boston, MA on Wednesday, March 4.

Passage Bio, Inc., today announced the pricing of its initial public offering of 12,000,000 shares of common stock at a public offering price of $18.00 per share.

Companion Medical today confirmed that it has received clearance from the FDA for its InPen bolus calculator for fixed dosing and meal estimation

Covetrus to Present at the Raymond James 41st Annual Institutional Investor Conference